Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Kathleen Somera-Molina_2023
Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New SPINRAZA (nusinersen) Long-Term Data in SMA
Shots: Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years The interview also discusses Biogen’s advances…
August 7, 2023
VIEWPOINTS_Mary Rodgers_2023
Mary Rodgers, Principal Research Scientist at Abbott Shares Insights on its Partnership with CLIMADE Consortium to Predict Disease Outbreaks Caused by Climate Change
Shots: Mary talked about Abbott's partnership Climate Amplified Disease and Epidemics (CLIMADE) consortium will use data science to predict, track and control diseases that may be amplified by climate change She then spoke about how Abbott and its partners in the Abbott Pandemic Defense Coalition will provide viral sequencing and testing data as part of…
August 3, 2023
VIEWPOINTS_Tahi Ahmadi1_Asud Khaliq2_2023
Tahi Ahmadi and Asud Khaliq Share their Views on EPKINLY (epcoritamab) U.S. FDA Approval in DLBCL
Shots: Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCL They then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY. EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…
August 2, 2023
VIEWPOINTS_Boaz Hirshberg_2023
Boaz Hirshberg, SVP, Clinical Development at Regeneron Shares Insights from the US FDA Approval of Evkeeza (evinacumab-dgnb)
Shots: Boaz spoke about the US FDA approval of Evkeeza (evinacumab-dgnb) to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH) Boaz also talked about the study design of the pivotal pediatric trial evaluating Evkeeza(evinacumab-dgnb) . He then extended his talk on HoFH and how Regeneron is creating awareness about the disease The…
July 31, 2023
VIEWPOINTS_Kathleen Somera-Molina1_2023
Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New Data Published about SPINRAZA
Shots: Kathleen spoke about the results of a new study published in Advances in Therapy evaluating real-world adherence to SPINRAZA (nusinersen) with its unique dosing schedule among people with spinal muscular atrophy (SMA) She also talked about the overall adherence rates to nusinersen. She highlighted that adherence was higher during the maintenance phase than the loading phase…
July 24, 2023
VIEWPOINTS_Ivy Weng_2023
Ivy Weng, Group VP, of Life Sciences at Komodo Health Shares Insights on its Collaboration with Intercept Pharmaceuticals
Shots: Ivy shared details of its collaboration with Intercept Pharmaceuticals and how Intercept is using Komodo’s tech platform and healthcare map for a retrospective real-world study on the long-term outcomes for Ocaliva She also talked about how pharma companies can utilize Komodo’s technology platform and how it supports rare disease research The interview gives an…
July 20, 2023
VIEWPOINTS_Nabil Abadir_2023
Nabil Abadir, CMO and Head of Global Medical Affairs at Amarin Corp Shares Insights from New Data Evaluating Vascepa/Vazkepa at ACC.23/WCC
Shots: Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCC He also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndrome The interview shows how Amarin is developing innovative therapies, increasing the…
July 18, 2023
VIEWPOINTS_Olivier Harari_2023
Olivier Harari, VP, Early Clinical Development at Regeneron Shares his Views on Pozelimab’s BLA Acceptance for the US FDA Priority Review
Shots: Olivier highlighted the P-II/III data based on which Regeneron’s BLA for Pozelimab was accepted by the US FDA under priority review to treat adults and children with CHAPLE disease CHAPLE disease is driven by an overactivation of the complement system due to CD55 deficiency. Pozelimab blocks the activity of complement factor C5 and prevents…
July 17, 2023
Load more